Table 2.

Patient and clinical characteristics

Variable	Total population N = 120 (%)
Sex
Female	99 (82.5)
Male	21 (17.5)
Age
<  45 years	29 (24.2)
45–65 years	65 (54.2)
>  65 years	26 (21.7)
Marital status
Single	16 (13.3)
Married	69 (57.5)
Divorced/living separated	24 (20.0)
Widowed	11 (9.2)
Educational level
Compulsory/lower secondary	31 (25.8)
Secondary school/apprenticeship	68 (56.7)
Higher education	9 (7.5)
Other	12 (10.0)
Monthly net income
<  1.000€ (1120$)	23 (19.2)
1.001–2000 € (1121–2240 $)	68 (56.7)
2001–3000 € (224—3360 $)	20 (16.7)
>  3000€ (>  3361$)	9 (7.5)
Disease duration
>  10 years	35 (42.5)
5–10 years	40 (33.3)
1–4 years	34 (30.8)
<  1 year	8 (6.7)
RA treatment
NSAID	51 (42.5)
sDMRAD	106 (88.3)
bDMRAD	38 (31.7)
Steroid	29 (24.2)
Other	11 (9.2)
Additional medication
No other medication	34 (28.3)
1–2 other medications	45 (37.5)
3–4 other medications	19 (37.5)
>  4 other medications	22 (18.3)
Presence of co-morbidity	62 (51.7)
	Mean (SD)
Patient self–assessed (VAS)	37.8 (30.3)
Disease activity	34.7 (29.4)
Pain	40.8 (29.0)
Functional disability	38.3 (31.0)
Fatigue

NSAID non–steroidal anti–inflammatory drug, sDMRAD synthetic disease–modifying antirheumatic drug, bDMARD biologic disease–modying antirheumatic drug, VAS Visual analogue scale 0–100